The GUL@LsiYY1@MZ platform targets PSMA-positive prostate cancer cells and exhibits cascaded magnetoresponsive activity, facilitating magnetothermal-triggered siYY1 release and cellular entry. The gene discussed is FOLH1; the disease is prostate carcinoma.